1. Home
  2. UHG vs ATYR Comparison

UHG vs ATYR Comparison

Compare UHG & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Homes Group Inc

UHG

United Homes Group Inc

HOLD

Current Price

$1.19

Market Cap

68.8M

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.83

Market Cap

73.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHG
ATYR
Founded
N/A
2005
Country
United States
United States
Employees
195
58
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
73.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UHG
ATYR
Price
$1.19
$0.83
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$3.67
AVG Volume (30 Days)
79.1K
968.9K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.64
52 Week High
$4.78
$7.29

Technical Indicators

Market Signals
Indicator
UHG
ATYR
Relative Strength Index (RSI) 40.93 50.84
Support Level $1.15 $0.68
Resistance Level $1.81 $0.86
Average True Range (ATR) 0.02 0.05
MACD 0.02 0.01
Stochastic Oscillator 77.78 76.19

Price Performance

Historical Comparison
UHG
ATYR

About UHG United Homes Group Inc

United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Share on Social Networks: